Business UpdateJun 10, 2026, 08:00 AM
Incannex Receives A$6.0M, Expects A$5.1M More from R&D Tax Incentive
AI Summary
Incannex Healthcare Inc. announced it has received over A$6.0 million from the Australian Government's Research and Development Tax Incentive Program and expects an additional A$5.1 million in future proceeds. This totals more than A$11.1 million in non-dilutive capital, significantly strengthening the company's balance sheet. The funds will enhance financial flexibility, supporting the advancement of key clinical development programs like IHL-42X and PSX-001, and ongoing capital allocation initiatives, including its active share repurchase program.
Key Highlights
- Received A$6,039,162.43 under the Australian Government's R&D Tax Incentive Program.
- Expects an additional approximately A$5.1 million in future R&D Tax Incentive proceeds in 2026.
- Total expected non-dilutive capital exceeds A$11.1 million.
- Strengthens the company's balance sheet and enhances financial flexibility.
- Supports advancement of key clinical assets, including IHL-42X and PSX-001.
- Funds ongoing shareholder-focused capital allocation initiatives, including share repurchase program.
Price Impact
More from IXHL